Compare Gilead Sciences, Inc. (GILD) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MGM Resorts International — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while MGM Resorts International trades at $29.27 (market cap $7.55B). The key difference: Gilead Sciences, Inc. is far larger — about 24.2× MGM Resorts International's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and MGM Resorts International for 91 Days on average.
| GILD | MGM | |
|---|---|---|
Market Cap | $182.40B | $7.55B |
Volume | 4,469,821 | 5,342,346 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $50.69 |
52-Week Low | $117.18 | $29.27 |
Typical Hold Time | 111 Days | 91 Days |
Enterprise Value | $205.46B | $34.85B |
Dividend Yield | 2.23% | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
MGM Resorts International (MGM) trades at $30.01, showing minimal daily movement. The stock is in a bearish technical trend with recent pressure following the collapse of a proposed acquisition by Barry Diller's People Inc. Fundamentally, revenue remains stable near $17.5 billion, but net income margin has compressed to 2.4% in 2025. The company maintains strong operating cash flow of $2.53 billion, though net cash flow was negative $338 million. Analyst sentiment is mixed but leans positive, with a consensus price target of $48.75 implying significant upside.
The investment outlook for MGM hinges on its ability to stabilize profitability and navigate deal uncertainty. The primary opportunity lies in the substantial discount to analyst targets, while risks include execution on potential acquisitions, competitive pressures in the gaming sector, and macroeconomic sensitivity. The stock's current valuation multiples, such as a P/E of 18.19, appear reasonable if earnings can recover.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
